Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14033127 | 0.88 | L3MBTL1 (0.42) | MAPK1PKMCYP1A2CYP2C9L3MBTL1 | |
| SCHEMBL9693821 | 0.88 | HSP90AA1 (0.39) | MAPK1PKMCYP1A2CYP2C9L3MBTL1 | |
| SCHEMBL27350623 | 0.85 | CYP1A2 (0.40) | MAPK1PKMCYP1A2CYP2C9L3MBTL1 | |
| SCHEMBL6306521 | 0.81 | TSHR (0.44) | MAPK1PKML3MBTL1ALDH1A1KMT2A | |
| SCHEMBL13160 | 0.80 | ESR2 (0.48) | MAPK1USP2ALDH1A1KMT2AKDM4E | |
| SCHEMBL20701469 | 0.80 | PDE4B (0.36) | KMT2ACYP2D6MEN1THRBSMN1; SMN2 | |
| SCHEMBL17014920 | 0.79 | — | — | |
| SCHEMBL1304158 | 0.78 | NOTUM (0.44) | CYP1A2L3MBTL1ALDH1A1KDM4EMAPT | |
| SCHEMBL3835092 | 0.76 | RAB9A (0.46) | CYP2C9ALDH1A1KMT2ATSHRCYP3A4 | |
| SCHEMBL27952380 | 0.76 | RIPK1 (0.34) | KDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141225-A1 | FUSED HETEROCYCLES AS 5-HT2A RECEPTOR AGONISTS | ONSERO THERAPEUTICS INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| CN-116426583-A | Method for preparing R-3-aminopiperidine and derivatives thereof by enzyme catalysis | 湖州颐盛生物科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4208465-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | Orexia Therapeutics Limited (GB) | 2023-07-12 | — | — | EP | disclosed |
| US-20230121497-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4096668-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2022051583-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS | OREXIA THERAPEUTICS LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
| WO-2021155264-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-9371275-B2 | 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis | SWEDISH PHARMA AB (SE) | 2016-06-21 | — | — | US | disclosed |
| US-9371275-B2 | 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis | SWEDISH PHARMA AB (SE) | 2016-06-21 | — | — | US | disclosed |
| US-9371275-B2 | 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis | SWEDISH PHARMA AB (SE) | 2016-06-21 | — | — | US | disclosed |
| EP-2337775-A1 | NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS | Swedish Pharma AB (SE) | 2011-06-29 | — | — | EP | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884107-B2 | Human Double Minute 2 (HDM2) protein inhibitors; anticancer agents | MERCK (US) | 2011-02-08 | — | — | US | disclosed |
| WO-2010024775-A1 | NEW 5-AMINOLEVULINIC ACID PRODRUGS FOR USE IN PHOTODYNAMIC THERAPY AND PHOTODYNAMIC DIAGNOSIS | SWEDISH PHARMA AB (SE) | 2010-03-04 | — | — | WO | disclosed |
| WO-2008005268-A1 | SUBSTITUTED PIPERIDINES THAT INCREASE P53 ACTIVITY AND THE USES THEREOF | SCHERING CORPORATION (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-5453422-A | Animal growth promoters | BAYER AKTIENGESELLSCHAFT (DE) | 1995-09-26 | — | — | US | disclosed |
| US-5284842-A | Active against gramnegative bacteria | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-08 | — | — | US | disclosed |
| US-5173484-A | Animal growth regulators | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004287-A1 | Substituted Piperidines that Increase P53 Activity and the Uses Thereof | TP53, MDM2, TP53BP1 | MAPK1 2877/4885PKM 3026/4885CYP1A2 2744/4885 |
| US-20230121497-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | MAPK1 4411/4885PKM 2012/4885CYP1A2 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.